A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Abstract The KRAS gene is frequently mutated in multiple cancer types, but it fell off the drug discovery radar for many years because of its inherent “undruggable” structure and undefined biological properties. As reported in the paper entitled “Suppression of KRas-mutant cancer through the combine...
| Autors principals: | , |
|---|---|
| Format: | Article |
| Idioma: | English |
| Publicat: |
BMC
2016-10-01
|
| Col·lecció: | Chinese Journal of Cancer |
| Matèries: | |
| Accés en línia: | http://link.springer.com/article/10.1186/s40880-016-0154-7 |